ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2021
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.
Open access · hybridAbstract readReview
In one paragraph
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 6 pooled it
14.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 6 syntheses or guidelines pooled it, 194 citations in OpenAlex.
- Tracking electrophysiological signatures of Alzheimer's disease: a systematic review of multimodal studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Functional and effective EEG connectivity patterns in Alzheimer's disease and mild cognitive impairment: a systematic review.Frontiers in aging neuroscience · 2025Pooled it
- The application of electroencephalogram in depression research: bibliometric and technological application analysis from 2005 to 2025.Frontiers in neuroscience · 2025Pooled it
- Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer's disease progression: a systematic review.Alzheimer's research & therapy · 2024Pooled it
- Parallel electrophysiological abnormalities due to COVID-19 infection and to Alzheimer's disease and related dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Pooled it
- Brain function effects of exercise interventions for cognitive decline: a systematic review and meta-analysis.Frontiers in neuroscience · 2023Pooled it
- Trial
- Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2024Trial
- Knowledge-Guided Deep Learning with Clinical EEG Biomarkers for Automated Dementia Detection and Staging.Diagnostics (Basel, Switzerland) · 2026Article
- Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers.Science advances · 2026Article
- Generalizability of EEG-Based DEMENTIA Classifiers: A Multicenter study of Alzheimer's, MCI, and FTD.medRxiv : the preprint server for health sciences · 2026Article
- Medial entorhinal-hippocampal desynchronization parallels the emergence of memory impairment in a mouse model of Alzheimer's disease pathology.Cell reports · 2026Article
- Virtual brain and electroencephalography explain the variance of memory alterations in mild cognitive impairment.Alzheimer's research & therapy · 2026Article
- Rethinking EEG biomarkers of brain disorders: a transdiagnostic dimensional view.Translational psychiatry · 2026Review
- A Two-Stage EEG Microstate Fusion Framework for Dementia Screening and Alzheimer's Disease/Frontotemporal Dementia Differentiation.Biosensors · 2026Article
- The electrophysiological basis of resting-state fMRI hyperconnectivity in early Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Quantitative EEG Assessment of Dependence-Related Neurophysiological Patterns Using Rule- and Score-Based Modeling in Substance Use Disorders.Medicina (Kaunas, Lithuania) · 2026Article
- EENet-RLA: An Explainable Prediction Learning Framework for Alzheimer's Disease Classification from EEG Signals.Brain topography · 2026Article
- Wearable EEG devices in the detection of mild cognitive impairment: a systematic review.NPJ digital medicine · 2026Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
60 authors at 20 institutions in 18 countries.
Claudio BabiloniDepartment of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-5245-9839
Xianghong ArakakiHuntington Medical Research Institutes, Pasadena, California, USA.
Hamed AzamiDepartment of Neurology and Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.
Karim BennysCentre Mémoire de Ressources et de Recherche (CMRR), Centre Hospitalier, Universitaire de Montpellier, Montpellier, France.
Katarzyna BlinowskaInstitute of Biocybernetics, Warsaw, Poland.
Laura BonanniDepartment of Neuroscience Imaging and Clinical Sciences and CESI, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy.
Ana BujanPsychological Neuroscience Lab, School of Psychology, University of Minho, Minho, Portugal.
Maria C CarrilloDivision of Medical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Andrzej CichockiSkolkowo Institute of Science and Technology (SKOLTECH), Moscow, Russia.
Jaisalmer de Frutos-LucasLaboratory of Cognitive and Computational Neuroscience, Center for Biomedical Technology, Universidad Complutense and Universidad Politécnica de Madrid, Madrid, Spain.
Claudio Del PercioDepartment of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.
Bruno DuboisDepartment of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l'hôpital, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France.
Rebecca EdelmayerDivision of Medical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Gary EganFoundation Director of the Monash Biomedical Imaging (MBI) Research Facilities, Monash University, Clayton, Australia.
Stephane EpelbaumDepartment of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l'hôpital, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France.
Javier EscuderoSchool of Engineering, Institute for Digital Communications, The University of Edinburgh, Edinburgh, UK.
Alan EvansDepartment of Neurology and Neurosurgery, McGill University, Montreal, Canada.
Francesca FarinaTrinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Keith FargoDivision of Medical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Alberto FernándezLaboratory of Cognitive and Computational Neuroscience, Center for Biomedical Technology, Universidad Complutense and Universidad Politécnica de Madrid, Madrid, Spain.
Raffaele FerriOasi Research Institute - IRCCS, Troina, Italy.
Giovanni FrisoniIRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Harald HampelGRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Sorbonne University, Paris, France.
Michael G HarringtonHuntington Medical Research Institutes, Pasadena, California, USA.
Vesna JelicDivision of Clinical Geriatrics, NVS Department, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Jaeseung JeongDepartment of Bio and Brain Engineering/Program of Brain and Cognitive Engineering Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.
Yang JiangDepartment of Behavioral Science, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Maciej KaminskiFaculty of Physics University of Warsaw and Nalecz, Warsaw, Poland.
Voyko KavcicInstitute of Gerontology, Wayne State University, Detroit, Michigan, USA.
Kerry KilbornSchool of Psychology, University of Glasgow, Glasgow, UK.
Sanjeev KumarGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Alice LamMGH Epilepsy Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Lew LimVielight Inc., Toronto, Ontario, Canada.
Roberta LizioIRCCS SDN, Napoli, Italy.
David LopezLaboratory of Cognitive and Computational Neuroscience, Center for Biomedical Technology, Universidad Complutense and Universidad Politécnica de Madrid, Madrid, Spain.
Susanna LopezDepartment of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.
Brendan LuceyWashington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Fernando MaestúLaboratory of Cognitive and Computational Neuroscience, Center for Biomedical Technology, Universidad Complutense and Universidad Politécnica de Madrid, Madrid, Spain.
William J McGeownSchool of Psychological Sciences and Health, University of Strathclyde, Glasgow, UK.
Ian McKeithNewcastle upon Tyne, Translational and Clinical Research Institute, Newcastle University, UK.
Davide Vito MorettiIRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Flavio NobiliDepartment of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy.
Giuseppe NoceIRCCS SDN, Napoli, Italy.
John OlichneyUC Davis Department of Neurology and Center for Mind and Brain, Davis, California, USA.
Marco OnofrjDepartment of Neuroscience Imaging and Clinical Sciences and CESI, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy.
Ricardo OsorioCenter for Brain Health, Department of Psychiatry, NYU Langone Medical Center, New York, New York, USA.
Mario Parra-RodriguezSchool of Psychological Sciences and Health, University of Strathclyde, Glasgow, UK.
Tarek RajjiGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Petra RitterBrain Simulation Section, Department of Neurology, Charité Universitätsmedizin and Berlin Institute of Health, Berlin, Germany.
Andrea SoricelliIRCCS SDN, Napoli, Italy.
Fabrizio StocchiIRCCS San Raffaele Pisana, Rome, Italy.
Ioannis TarnanasGlobal Brain Health Institute, University of California San Francisco, San Francisco, USA.
John Paul TaylorNewcastle upon Tyne, Translational and Clinical Research Institute, Newcastle University, UK.
Stefan TeipelDepartment of Psychosomatic Medicine, University of Rostock, Rostock, Germany.
Federico TucciDepartment of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.
Mitchell Valdes-SosaCuban Neuroscience Center, Havana, Cuba.
Pedro Valdes-SosaCuban Neuroscience Center, Havana, Cuba.
Marco WeiergräberExperimental Neuropsychopharmacology, BfArM), Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.
Gorsev YenerDepartments of Neurosciences and Department of Neurology, Dokuz Eylül University Medical School, Izmir, Turkey.
Bahar GuntekinDepartment of Biophysics, School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Universidad Politécnica de Madrid · ESAlzheimer's Association · USSapienza University of Rome · ITCentre for Addiction and Mental Health · CACentre National de la Recherche Scientifique · FRHarvard University · USHuntington Medical Research Institutes · USNewcastle University · GBSDN Istituto di Ricerca Diagnostica e Nucleare · ITUniversity of Chieti-Pescara · ITUniversity of Strathclyde · GBBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DECentre Hospitalier Universitaire de Montpellier · FRCentro San Giovanni di Dio Fatebenefratelli · ITCuban Neuroscience Center · CUDokuz Eylül University · TRFederal Institute for Drugs and Medical Devices · DEGerman Center for Neurodegenerative Diseases · DEHealthInsight · USInstitute of Biocybernetics and Biomedical Engineering · PL
Funding
Research Education ComponentP30AG066512 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSHUA CHODOSH · 2020 to 2026
$28.4MCognitive challenge to reveal systemic neurophysiology biomarkers in pre-symptomatic Alzheimer’s diseaseR01AG063857 · NIA · HUNTINGTON MEDICAL RESEARCH INSTITUTES · PI ARAKAKI, XIANGHONG, KLONER, ROBERT A · 2021 to 2025
$3.8MCommunity-based approach to Early Identification of transitions to Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) in African AmericansR01AG054484 · NIA · WAYNE STATE UNIVERSITY · PI KAVCIC, VOYKO · 2018 to 2022
$3.3MSLEEP QUALITY AND HUMAN AMLYOID-BETA KINETICSK76AG054863 · NIA · WASHINGTON UNIVERSITY · PI LUCEY, BRENDAN PATRICK · 2016 to 2020
$982kNIA NIH HHS K76 AG054863NIA NIH HHS P30 AG066512NIA NIH HHS R01 AG054484NIA NIH HHS R01 AG063857
Abstract
The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and "interrelatedness" at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and "interrelatedness" rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.
Indexed as
Clinical Trials as TopicAlzheimer DiseaseBrainCognitive DysfunctionDisease ProgressionElectroencephalographyHumansAlzheimer's diseasebiomarkersclinical trialsdementiaelectroencephalography (EEG)eyes-closed resting state conditionThe Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.